Gemcitabine, an inhibitor of topoisomerase I, serves as a first-line adjuvant chemotherapy for advanced PDAC [178] while STAT3, a transcription factor associated with CSC renewal, interacts with the CD44 receptor overexpressed in tumor cells. The gene discussed is STAT3; the disease is neoplasm.